Literature DB >> 29302412

Salvage video-assisted thoracoscopic lobectomy for isolated local relapse after stereotactic body radiotherapy for early stage non-small cell lung cancer: technical aspects and perioperative management.

Masatsugu Hamaji1, Toyofumi-Fengshi Chen-Yoshikawa1, Yukinori Matsuo2, Hideki Motoyama1, Kyoko Hijiya1, Toshi Menju1, Akihiro Aoyama1, Toshihiko Sato1, Makoto Sonobe1, Hiroshi Date1.   

Abstract

Limited data is available on salvage surgery for local relapse (LR) after stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC). We aimed to characterize treatment options and clarify long-term outcomes of isolated LR after SBRT for patients with clinical stage I NSCLC. Herein, we discuss technical aspects, perioperative management, and postoperative follow-up of two patients of the 12 patients undergoing salvage surgery for LR after SBRT at Kyoto University between 1999 and 2013. A 76-year-old male, 15 months after SBRT, underwent a salvage right upper lobectomy combined with adjacent right lower lobe wedge resection via video-assisted thoracoscopic surgery (VATS) for a 5.0-cm mass. Local recurrence was found 5 years after salvage surgery and treated with repeat SBRT, however he died from multiple distant metastases. An 85-year-old male, 14 months after SBRT, underwent a salvage left upper lobectomy via VATS for a 3.5-cm mass. Moderate intrapleural adhesion was noted and required careful dissection on the mediastinum. He is alive with no recurrence at 2 years from salvage surgery. Salvage VATS lobectomy was feasible after SBRT in two patients. Long-term follow-up and continued discussions at multidisciplinary conferences are required.

Entities:  

Keywords:  Non-small cell lung cancer (NSCLC); radiotherapy; surgery

Year:  2017        PMID: 29302412      PMCID: PMC5678202          DOI: 10.21037/jovs.2017.04.02

Source DB:  PubMed          Journal:  J Vis Surg        ISSN: 2221-2965


  15 in total

1.  Surgical salvage following stereotactic body radiotherapy for early-stage NSCLC.

Authors:  Z Allibhai; B C J Cho; M Taremi; S Atallah; A Hope; D Hwang; S Keshavjee; M Tsao; K Yasufuku; S-W Kim; A Bezjak
Journal:  Eur Respir J       Date:  2012-04       Impact factor: 16.671

2.  Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.

Authors:  Sashendra Senthi; Frank J Lagerwaard; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  Lancet Oncol       Date:  2012-06-22       Impact factor: 41.316

3.  Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer: Importance of Salvage Surgery.

Authors:  Masatsugu Hamaji; Fengshi Chen; Yukinori Matsuo; Nami Ueki; Masahiro Hiraoka; Hiroshi Date
Journal:  J Thorac Oncol       Date:  2015-11       Impact factor: 15.609

4.  Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.

Authors:  Achilles J Fakiris; Ronald C McGarry; Constantin T Yiannoutsos; Lech Papiez; Mark Williams; Mark A Henderson; Robert Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-27       Impact factor: 7.038

5.  Thoracoscopic lobectomy is associated with acceptable morbidity and mortality in patients with predicted postoperative forced expiratory volume in 1 second or diffusing capacity for carbon monoxide less than 40% of normal.

Authors:  Bryan M Burt; Andrzej S Kosinski; Joseph B Shrager; Mark W Onaitis; Tracey Weigel
Journal:  J Thorac Cardiovasc Surg       Date:  2014-03-13       Impact factor: 5.209

6.  Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.

Authors:  Traves D Crabtree; Chadrick E Denlinger; Bryan F Meyers; Issam El Naqa; Jennifer Zoole; A Sasha Krupnick; Daniel Kreisel; G Alexander Patterson; Jeffrey D Bradley
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-18       Impact factor: 5.209

7.  VATS lobectomy has better perioperative outcomes than open lobectomy: CALGB 31001, an ancillary analysis of CALGB 140202 (Alliance).

Authors:  Chukwumere E Nwogu; Jonathan D'Cunha; Herbert Pang; Lin Gu; Xiaofei Wang; William G Richards; Linda J Veit; Todd L Demmy; David J Sugarbaker; Leslie J Kohman; Scott J Swanson
Journal:  Ann Thorac Surg       Date:  2014-12-10       Impact factor: 4.330

8.  Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer.

Authors:  Cliff G Robinson; Todd A DeWees; Issam M El Naqa; Kimberly M Creach; Jeffrey R Olsen; Traves D Crabtree; Bryan F Meyers; Varun Puri; Jennifer M Bell; Parag J Parikh; Jeffrey D Bradley
Journal:  J Thorac Oncol       Date:  2013-02       Impact factor: 15.609

9.  Salvage stereotactic body radiation therapy (SBRT) for local failure after primary lung SBRT.

Authors:  Jason W D Hearn; Gregory M M Videtic; Toufik Djemil; Kevin L Stephans
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-10       Impact factor: 7.038

10.  Salvage stereotactic body radiotherapy for locally recurrent non-small cell lung cancer after sublobar resection and i(125) vicryl mesh brachytherapy.

Authors:  Beant S Gill; David A Clump; Steven A Burton; Neil A Christie; Matthew J Schuchert; Dwight E Heron
Journal:  Front Oncol       Date:  2015-05-11       Impact factor: 6.244

View more
  2 in total

Review 1.  Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research.

Authors:  Eugenia Vlaskou Badra; Michael Baumgartl; Silvia Fabiano; Aurélien Jongen; Matthias Guckenberger
Journal:  Transl Lung Cancer Res       Date:  2021-04

2.  Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT.

Authors:  Yasutaka Ogawa; Yuta Shibamoto; Chisa Hashizume; Takuhito Kondo; Hiromitsu Iwata; Natsuo Tomita; Hiroyuki Ogino
Journal:  Radiat Oncol       Date:  2018-07-28       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.